Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
暂无分享，去创建一个
M. Hennerici | G. Samsa | L. Goldstein | H. Sillesen | P. Amarenco | K. Welch | J. Zivin | A. Callahan | R. Scott | I. Altafullah | Michael Messig | M. MacLeod | Lucy Y Ledbetter | MD IRA SHOULSON | MD Alfred Callahan | MD Pierre Amarenco | MD Larry B. Goldstein | MD DMSc Henrik Sillesen | PhD Mike Messig | PhD Gregory P. Samsa | MD Irfan Altafullah | MD Lucy Y. Ledbetter | PhD MBChB Mary J. MacLeod | BMedSc Russell Scott | MD PhD Michael Hennerici | MD Justin A. Zivin | PhD K. Michael | MD ChB A. Welch